Effect of amifostine on efficacy and hematologic toxicity in patients with advan ced non-small-cell lung cancer treated with chemotherapy
- VernacularTitle:阿米福汀对晚期非小细胞肺癌化疗疗效和血液毒性的影响
- Author:
Kai CHEN
;
Qincai WANG
;
Min TAO
- Publication Type:Journal Article
- Keywords:
lung cancer;
amifostine;
mitomycin;
vindesine;
cisplatin;
chemotherapy;
chemoprotectant
- From:China Oncology
2000;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To study the effect of amifostine on ef ficacy in patients with advanced non-small-cell lung cancer(NSCLC) treated w ith chemotherapy and the protection of amifostine on myelosuppression induced by chemotherapy and to investigate major adverse reaction induced by amfostine. Methods:33 patients with advanced NSCLC were randomly divided i nto protection group (amosfostine + MMC +VDS + DDP) and control group (MMC + VDS + DDP), The regimen was given every 4 weeks , All enrolled patients were evalua ted for efficacy and hematologic toxicity after 3 cycles of treatment , Patients in both groups were well-matched for baseline disease characteristics. Results:In protection group (PG) , the response rate was 40% (1 CR , 5 PR , 6 NC , 3 PD), whereas in control group (CG) , the response rate was 33.3% (0 CR , 5 CR , 8 NC , 2 PD), the differentce of response rates betwee n two the groups was not statistically significant (P=0.705). The minimum wh ite blood cell (WBC) counts after chemotherapy in treatment group and in control group were (3.387?1.169)?109/L and (2.46?0.98)?109/L respectively (P =0.026). The minimum blood platelet cell (BPC) counts in PG and in CG were (11 4.53?48.24)?109 /L and (88.2?32.83)?109 /L respectively (P=0.091) . The minimum hemoglobin (HB) counts in CG and in CG were (94.4?14.69)g/L and (89 .33?13.98)g/L respectively (P=0.341). Grade (Ⅱ-Ⅳ) leukopenia rate in PG and in CG were 66.7% (10/15) and 33.3% (5/15) respectively (P= 0.068), Gr ade (Ⅱ-Ⅳ) thrombocytopenia rate in PG and in CG were 33.3% (5/15) and 20% (3/ 15) respectively (P= 0.409), Grade (Ⅱ-Ⅳ) hypochromia rate in PG and in CG were 53.3% (8/15) and 46.7% (7/15) respectively (P= 0.715). Major ad verse effects of amifostine were mild hypotension , nausea and vomiting , dizzin ess , malaise etc. Conclusions:Amifostine does not reduce the efficacy of chemothe rapy in patients with advanced NSCLC , it can reduce the hematologic toxicity as sociated with chemotherapy of MVP regimen , the adverse effects of amifostine ar e mild.
